Mendus has reported its Q225 results. During the period, it made continued progress on the lead prog...
Solteq’s Q2 results fell short of our expectations.
Despite a weaker-than-expected quarter in terms of revenue and profitability, we are raising our sal...
Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Asceli...
* Stable financials * Orviglance FDA submission in early September * Neutral share price reaction ex...
* Sales -4% and adj. EBIT -11% vs ABGSCe * DOCS adoption 23% of municipalities * Consensus adj.
Redeye provides an initial comment on the Q2 2025 report from Catella.
Redeye comments on Teneo AI’s Q2, showing flat underlying q/q ARR growth.
* Q2 EBIT of SEK 315m, +11% vs. ABGSC and +7% vs. consensus * Announces buyback of bonds of max SEK ...
Redeye comments on Better Collective’s Q2-results which were slightly below our forecast owing mainl...
Egetis has launched Emcitate in Germany. The progress made in the US include advancing the US study ...
Redeye comments on SynAct Biopharma’s Q2 report. After a directed share issue, loan agreement with H...
Redeye provides an update following Paxman’s Q2 2025 report.
Redeye comments on the positive news that Saniona has outlicensed SAN2355 to Jazz Pharmaceuticals in...
- Report out 26 August - Q2e EBIT of SEK 103m - Onshore wind project (147 MW), Pienava in Latvia, so...
